According to a new market research report, ‘NGS Automation Market By Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) - Global Forecast to 2029', published by Meticulous Research®, the NGS automation market is expected to grow at a CAGR of 13.4% from 2022 to reach $940.2 million by 2029.
Next-generation sequencing (NGS) has revolutionized the way we understand genomics, allowing for faster, cheaper and more accurate DNA sequencing. However, despite ongoing advancements in high-throughput sequencing, the library preparation step remains a bottleneck in the NGS workflow. Library preparation involves numerous repetitive steps that require small volumes to be pipetted with high precision, making it prone to manual errors that can compromise the entire NGS process.
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5271
Automation of library preparation can significantly increase efficiency, generate more consistent results and improve lab efficiency. NGS automation also helps maintain turnaround times and increase sample throughput. The increasing demand for automation in NGS workflow, the rising incidences of cancer, and increasing R&D investments and healthcare expenditure are the main drivers of the NGS automation market.
However, there are challenges to the growth of this industry, such as regulatory and standardization concerns in diagnostic testing and the requirement of high-skilled personnel to operate automation software. Nevertheless, the benefits of NGS automation are undeniable, and it has become an essential tool for modern genomic research and clinical diagnostics.
Based on product, in 2022, the workstation/robotic platform segment is estimated to account for the largest share of this market. The large share of this segment is attributed to factors such as the increasing demand for the automation of NGS workflow, the rising adoption of automation workstations/robotic platforms by pharmaceutical and biotechnology companies and in diagnostic laboratories, and the increasing number of funding by governments for drug discovery and research.
Based on application, in 2022, the drug discovery segment is estimated to account for the largest share of this market. The large share of this segment is attributed to the increasing utilization of NGS for identifying novel drug targets and developing therapeutic techniques that target specific genes and proteins, such as targeted therapies, gene therapies, and oligonucleotide therapies, resulting in the increased demand for automation of NGS workflow.
Based on sequencing type, in 2022, the whole genome sequencing segment is estimated to account for the largest share of this market. The large share of this segment is attributed to the advantages of whole-genome sequencing (WGS) in discovery applications, such as identifying causative variants and novel genome assembly, and the ability of this method to detect single nucleotide variants, insertions/deletions, copy number changes, and large structural variants.
Speak to Analysts: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5271
based on end user, the pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the market. The large share of this segment is attributed to the rising R&D expenditure and the growing demand for new drug discoveries using advanced technologies.
In 2022, North America is estimated to account for the largest share of the NGS automation market, followed by Europe and Asia-Pacific. North America’s major market is attributed to the rising demand for NGS automation among researchers and scientists, the governments’ increasing support and investments to enhance genome sequencing infrastructure in the region, and the growing number of R&D investments by pharmaceutical and biopharmaceutical companies.
Key players: operating in the NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PRIMADAG SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland).
Quick Buy- https://www.meticulousresearch.com/Checkout/27804657
Scope of the Report:
NGS Automation Market, by Product
• Workstation/Robotic Platform
• Reagents & Consumables
NGS Automation Market, by Application
• Drug Discovery
• Clinical Diagnostics
o Oncology
o Infectious Diseases
o Reproductive Health
o Other Clinical Diagnostics
• Other Applications
NGS Automation Market, by Sequencing Type
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Genome Sequencing
• Others
NGS Automation Market, by End User
• Hospitals & Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Others End Users
To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/ngs-automation-market-5271
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research